PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Investigating the Prevalence of Comorbidities in MS Clinical Trials
MP3•Episode home
Manage episode 408359205 series 82212
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Host: Ashley Baker, MSN, PMHNP
Guest: Amber Salter, PhD
In 2016, an International Advisory Committee on Clinical Trials in Multiple Sclerosis (MS) recommended that comorbidities be more clearly and consistently described in enrolled clinical trial populations for common comorbidities so we can better understand the applicability of these trial findings to those in clinical practice. And so a recent study investigated the prevalence of comorbidities in MS clinical trial populations and found that 46 percent of the participants had one or more comorbid condition. Dive further into the findings from the study that was presented at the 2023 joint ECTRIMS-ACTRIMS meeting with Ashley Baker and Dr. Amber Salter, Associate Professor of Biostatistics at the University of Texas Southwestern Medical Center.
…
continue reading
Guest: Amber Salter, PhD
In 2016, an International Advisory Committee on Clinical Trials in Multiple Sclerosis (MS) recommended that comorbidities be more clearly and consistently described in enrolled clinical trial populations for common comorbidities so we can better understand the applicability of these trial findings to those in clinical practice. And so a recent study investigated the prevalence of comorbidities in MS clinical trial populations and found that 46 percent of the participants had one or more comorbid condition. Dive further into the findings from the study that was presented at the 2023 joint ECTRIMS-ACTRIMS meeting with Ashley Baker and Dr. Amber Salter, Associate Professor of Biostatistics at the University of Texas Southwestern Medical Center.
133 episodes
MP3•Episode home
Manage episode 408359205 series 82212
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Host: Ashley Baker, MSN, PMHNP
Guest: Amber Salter, PhD
In 2016, an International Advisory Committee on Clinical Trials in Multiple Sclerosis (MS) recommended that comorbidities be more clearly and consistently described in enrolled clinical trial populations for common comorbidities so we can better understand the applicability of these trial findings to those in clinical practice. And so a recent study investigated the prevalence of comorbidities in MS clinical trial populations and found that 46 percent of the participants had one or more comorbid condition. Dive further into the findings from the study that was presented at the 2023 joint ECTRIMS-ACTRIMS meeting with Ashley Baker and Dr. Amber Salter, Associate Professor of Biostatistics at the University of Texas Southwestern Medical Center.
…
continue reading
Guest: Amber Salter, PhD
In 2016, an International Advisory Committee on Clinical Trials in Multiple Sclerosis (MS) recommended that comorbidities be more clearly and consistently described in enrolled clinical trial populations for common comorbidities so we can better understand the applicability of these trial findings to those in clinical practice. And so a recent study investigated the prevalence of comorbidities in MS clinical trial populations and found that 46 percent of the participants had one or more comorbid condition. Dive further into the findings from the study that was presented at the 2023 joint ECTRIMS-ACTRIMS meeting with Ashley Baker and Dr. Amber Salter, Associate Professor of Biostatistics at the University of Texas Southwestern Medical Center.
133 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.